Theriva Biologics Statistics
Total Valuation
TOVX has a market cap or net worth of $3.17 million. The enterprise value is -$11.50 million.
Important Dates
The last earnings date was Tuesday, November 12, 2024, before market open.
| Earnings Date | Nov 12, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
TOVX has 2.78 million shares outstanding. The number of shares has increased by 29.99% in one year.
| Current Share Class | 2.78M |
| Shares Outstanding | 2.78M |
| Shares Change (YoY) | +29.99% |
| Shares Change (QoQ) | +46.23% |
| Owned by Insiders (%) | 0.48% |
| Owned by Institutions (%) | 12.86% |
| Float | 2.49M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 0.12 |
| P/TBV Ratio | 0.13 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 2.67, with a Debt / Equity ratio of 0.07.
| Current Ratio | 2.67 |
| Quick Ratio | 2.51 |
| Debt / Equity | 0.07 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -77.91% and return on invested capital (ROIC) is -34.86%.
| Return on Equity (ROE) | -77.91% |
| Return on Assets (ROA) | -24.85% |
| Return on Capital (ROIC) | -34.86% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$1.21M |
| Employee Count | 22 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | -424,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -92.27% in the last 52 weeks. The beta is 1.30, so TOVX's price volatility has been higher than the market average.
| Beta (5Y) | 1.30 |
| 52-Week Price Change | -92.27% |
| 50-Day Moving Average | 1.44 |
| 200-Day Moving Average | 5.63 |
| Relative Strength Index (RSI) | 36.16 |
| Average Volume (20 Days) | 97,324 |
Short Selling Information
The latest short interest is 90,953, so 3.27% of the outstanding shares have been sold short.
| Short Interest | 90,953 |
| Short Previous Month | 96,864 |
| Short % of Shares Out | 3.27% |
| Short % of Float | 3.66% |
| Short Ratio (days to cover) | 0.03 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -20.21M |
| Pretax Income | -20.35M |
| Net Income | -26.69M |
| EBITDA | -20.06M |
| EBIT | -20.21M |
| Earnings Per Share (EPS) | -$32.52 |
Full Income StatementBalance Sheet
The company has $16.41 million in cash and $1.74 million in debt, giving a net cash position of $14.67 million or $5.27 per share.
| Cash & Cash Equivalents | 16.41M |
| Total Debt | 1.74M |
| Net Cash | 14.67M |
| Net Cash Per Share | $5.27 |
| Equity (Book Value) | 24.64M |
| Book Value Per Share | 9.41 |
| Working Capital | 12.21M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$18.79 million and capital expenditures -$57,000, giving a free cash flow of -$18.84 million.
| Operating Cash Flow | -18.79M |
| Capital Expenditures | -57,000 |
| Free Cash Flow | -18.84M |
| FCF Per Share | -$6.77 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |